Drugs that contain Naldemedine Tosylate

1. List of Symproic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46375 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Oct, 2026

(3 years from now)

USRE46365 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Jan, 2028

(4 years from now)

US9108975 BDSI Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Nov, 2031

(8 years from now)

US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2022

NCE-1 date: March, 2021

Market Authorisation Date: 23 March, 2017

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in